Author:
Ireland Luu D.,Allen Rebecca H.
Publisher
Springer International Publishing
Reference78 articles.
1. Amsden G, Mohamed M, Menhinick A. Effect of hormonal contraceptives on the pharmacokinetics of trovafloxacin in women. Clin Drug Investig. 2001;21(4):281–6.
2. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol. 1981;113(3):203–14.
3. Brody SA, Turkes A, Goldzieher JW. Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are “low-dose” pills really lower? Contraception. 1989;40(3):269–84.
4. Casper RF, Dodin S, Reid RL, Study Investigators. The effect of 20 μg of ethinyl estradiol/1 mg norethindrone acetate (Minestrin™), a low-dose oral contraceptive on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause. 1997;49:47–55.
5. Centers for Disease Control and Prevention (CDC). U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–55.